Author: admin

  • New phages spark hope against hospital superbug • healthcare-in-europe.com

    New phages spark hope against hospital superbug • healthcare-in-europe.com

    Phages attacking bacteria under the microscope

    Image source: University of Southampton 

    Different phages work a bit like different keys – each one can only “unlock” (infect) certain strains of the bacteria. The Klebsiella Phage Collection…

    Continue Reading

  • Asian shares advance after Wall Street gets a lift from hopes for a Fed rate cut

    Asian shares advance after Wall Street gets a lift from hopes for a Fed rate cut

    BANGKOK — Asian shares mostly gained on Tuesday after U.S. stocks rallied on hopes the Federal Reserve will cut interest rates soon.

    U.S. futures edged lower and oil prices also declined.

    Tokyo’s Nikkei 225 was nearly unchanged at 48,628.85, after reopening from a holiday.

    A plunge in technology giant SoftBank’s shares weighed on the market. It fell 10.3% on concerns that returns from its heavy investments in OpenAI may be threatened by the next generation Gemini artificial intelligenc e model that Google launched last week.

    In South Korea, the Kospi gained 0.3% to 3,859.12. Taiwan’s Taiex jumped 1.5%.

    Chinese markets also advanced. In Hong Kong, the Hang Seng climbed 0.4% to 25,821.47, while the Shanghai Composite index jumped 0.9% to 3,872.45.

    E-commerce giant Alibaba, which was due to report its earnings late Tuesday, gained 1.6%.

    Australia’s S&P/ASX rebounded to edge 0.1% higher, closing at 8,537.00.

    U.S. markets will be closed on Thursday for the Thanksgiving holiday. A day later, it’s on to the rush of Black Friday and Cyber Monday.

    The U.S. stock market rallied on Monday, at the start of a week with shortened trading because of the Thanksgiving holiday.

    The S&P 500 climbed 1.5% to 6,705.12 in one of its best days since the summer. The Dow Jones Industrial Average rose 0.4% to 46,448.27, and the Nasdaq composite jumped 2.7% to 22,872.01.

    Stocks got a lift from rising hopes that the Fed will cut its main interest rate again at its next meeting in December, a move that could boost the economy and investment prices.

    The market also benefited from strength for stocks caught up in the artificial-intelligence frenzy. Alphabet, which has been getting praise for its newest Gemini AI model, rallied 6.3% and was one of the strongest forces lifting the S&P 500. Nvidia rose 2.1%.

    Monday’s gains followed sharp swings in recent weeks, not just day to day but also hour to hour, caused by uncertainty about what the Fed will do with interest rates and whether too much money is pouring into AI and creating a bubble. All the worries are creating the biggest test for investors since an April sell-off, when President Donald Trump shocked the world with his “Liberation Day” tariffs.

    Despite all the recent fear, the S&P 500 remains within 2.7% of its record set last month.

    Several tests for the market lie ahead this week. One of the biggest will arrive Tuesday when the U.S. government will deliver data on inflation at the wholesale level in September.

    Economists expect it to show a 2.6% rise in prices from a year earlier, the same as in August. A higher-than-expected reading could deter the Fed from cutting its main interest rate in December for a third time this year, because lower rates can worsen inflation. Some Fed officials have already argued against a December cut in part because inflation has stubbornly remained above their 2% target.

    Traders are nevertheless betting on a nearly 85% probability that the Fed will cut rates next month, up from 71% on Friday and from less than a coin flip’s chance seen a week ago, according to data from CME Group.

    In other dealings early Tuesday, U.S. benchmark crude oil lost 25 cents to $58.59 per barrel. Brent crude, the international standard, shed 30 cents to $62.42 per barrel.

    The dollar fell to 156.70 Japanese yen from 156.91 yen. The euro slipped to $1.1517 from $1.1521.

    Bitcoin fell 1.1% to $88,100. It was near $125,000 last month.

    Continue Reading

  • Error Page

    Error PageSecurity Violation (503)

    newsroom.st.com | RBZ Access denied (403)

    Current session has been terminated.

    ALERT! You are entering into a secured area! Your IP, Login Time, Username has been noted and has been sent to the…

    Continue Reading

  • Primitive War review – it’s Green Berets vs dinosaurs in cheerfully cheesy Vietnam war gorefest | Film

    Primitive War review – it’s Green Berets vs dinosaurs in cheerfully cheesy Vietnam war gorefest | Film

    Aimed squarely and unabashedly at viewers who love soldiers, gore and dinosaurs – as well as dinosaurs goring soldiers – this adaptation of Ethan Pettus’s 2017 novel is deeply repetitive but weirdly watchable. Although shot in Australia…

    Continue Reading

  • Progress on share buyback programme

    Progress on share buyback programme

    Amsterdam,

    ING announced today that, as part of our €1.1 billion share buyback programme announced on 30 October 2025, in total 2,767,892 shares were repurchased during the week of 17 November up to and including 21 November 2025.

    The shares were repurchased at an average price of €21.60 for a total amount of €59,777,931.11.

    In line with the purpose of the programme to reduce the share capital of ING, the total number of shares repurchased under this programme to date is 7,899,202 at an average price of €22.02 for a total consideration of €173,950,206.98. To date approximately 15.81% of the maximum total value of the share buyback programme has been completed.

    For detailed information on the daily repurchased shares, individual share purchase transactions and weekly reports, see share buy back programme.

    Note for editors

    More on investor information, go to the investor relations section on this site.

    For news updates, go to the newsroom on this site or via X (@ING_news feed).

    For ING photos such as board members, buildings, go to Flickr.

    ING PROFILE

    ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank. The purpose of ING Bank is: empowering people to stay a step ahead in life and in business. ING Bank’s more than 60,000 employees offer retail and wholesale banking services to customers in over 100 countries.

    ING Group shares are listed on the exchanges of Amsterdam (INGA NA, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).

    ING aims to put sustainability at the heart of what we do. Our policies and actions are assessed by independent research and ratings providers, which give updates on them annually. ING’s ESG rating by MSCI was reconfirmed by MSCI as ‘AA’ in August 2024 for the fifth year. As of December 2023, in Sustainalytics’ view, ING’s management of ESG material risk is ‘Strong’. Our current ESG Risk Rating, is 17.2 (Low Risk). ING Group shares are also included in major sustainability and ESG index products of leading providers. Here are some examples: Euronext, STOXX, Morningstar and FTSE Russell. Society is transitioning to a low-carbon economy. So are our clients, and so is ING. We finance a lot of sustainable activities, but we still finance more that’s not. Follow our progress on ing.com/climate.

    Important legal information

    Elements of this press release contain or may contain information about ING Groep N.V. and/ or ING Bank N.V. within the meaning of Article 7(1) to (4) of EU Regulation No 596/2014 (‘Market Abuse Regulation’).

    ING Group’s annual accounts are prepared in accordance with International Financial Reporting Standards as adopted by the European Union (‘IFRS- EU’). In preparing the financial information in this document, except as described otherwise, the same accounting principles are applied as in the 2024 ING Group consolidated annual accounts. All figures in this document are unaudited. Small differences are possible in the tables due to rounding.

    Certain of the statements contained herein are not historical facts, including, without limitation, certain statements made of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Actual results, performance or events may differ materially from those in such statements due to a number of factors, including, without limitation: (1) changes in general economic conditions and customer behaviour, in particular economic conditions in ING’s core markets, including changes affecting currency exchange rates and the regional and global economic impact of the invasion of Russia into Ukraine and related international response measures (2) changes affecting interest rate levels (3) any default of a major market participant and related market disruption (4) changes in performance of financial markets, including in Europe and developing markets (5) fiscal uncertainty in Europe and the United States (6) discontinuation of or changes in ‘benchmark’ indices (7) inflation and deflation in our principal markets (8) changes in conditions in the credit and capital markets generally, including changes in borrower and counterparty creditworthiness (9) failures of banks falling under the scope of state compensation schemes (10) non- compliance with or changes in laws and regulations, including those concerning financial services, financial economic crimes and tax laws, and the interpretation and application thereof (11) geopolitical risks, political instabilities and policies and actions of governmental and regulatory authorities, including in connection with the invasion of Russia into Ukraine and the related international response measures (12) legal and regulatory risks in certain countries with less developed legal and regulatory frameworks (13) prudential supervision and regulations, including in relation to stress tests and regulatory restrictions on dividends and distributions (also among members of the group) (14) ING’s ability to meet minimum capital and other prudential regulatory requirements (15) changes in regulation of US commodities and derivatives businesses of ING and its customers (16) application of bank recovery and resolution regimes, including write down and conversion powers in relation to our securities (17) outcome of current and future litigation, enforcement proceedings, investigations or other regulatory actions, including claims by customers or stakeholders who feel misled or treated unfairly, and other conduct issues (18) changes in tax laws and regulations and risks of non-compliance or investigation in connection with tax laws, including FATCA (19) operational and IT risks, such as system disruptions or failures, breaches of security, cyber-attacks, human error, changes in operational practices or inadequate controls including in respect of third parties with which we do business and including any risks as a result of incomplete, inaccurate, or otherwise flawed outputs from the algorithms and data sets utilized in artificial intelligence (20) risks and challenges related to cybercrime including the effects of cyberattacks and changes in legislation and regulation related to cybersecurity and data privacy, including such risks and challenges as a consequence of the use of emerging technologies, such as advanced forms of artificial intelligence and quantum computing (21) changes in general competitive factors, including ability to increase or maintain market share (22) inability to protect our intellectual property and infringement claims by third parties (23) inability of counterparties to meet financial obligations or ability to enforce rights against such counterparties (24) changes in credit ratings (25) business, operational, regulatory, reputation, transition and other risks and challenges in connection with climate change, diversity, equity and inclusion and other ESG-related matters, including data gathering and reporting and also including managing the conflicting laws and requirements of governments, regulators and authorities with respect to these topics (26) inability to attract and retain key personnel (27) future liabilities under defined benefit retirement plans (28) failure to manage business risks, including in connection with use of models, use of derivatives, or maintaining appropriate policies and guidelines (29) changes in capital and credit markets, including interbank funding, as well as customer deposits, which provide the liquidity and capital required to fund our operations, and (30) the other risks and uncertainties detailed in the most recent annual report of ING Groep N.V. (including the Risk Factors contained therein) and ING’s more recent disclosures, including press releases, which are available on www.ING.com.

    This document may contain ESG-related material that has been prepared by ING on the basis of publicly available information, internally developed data and other third-party sources believed to be reliable. ING has not sought to independently verify information obtained from public and third-party sources and makes no representations or warranties as to accuracy, completeness, reasonableness or reliability of such information. This document may also discuss one or more specific transactions and/or contain general statements about ING’s ESG approach. The approach and criteria referred to in this document are intended to be applied in accordance with applicable law. Due to the fact that there may be different or even conflicting laws, the approach, criteria or the application thereof, could be different.

    Materiality, as used in the context of ESG, is distinct from, and should not be confused with, such term as defined in the Market Abuse Regulation or as defined for Securities and Exchange Commission (‘SEC’) reporting purposes. Any issues identified as material for purposes of ESG in this document are therefore not necessarily material as defined in the Market Abuse Regulation or for SEC reporting purposes. In addition, there is currently no single, globally recognized set of accepted definitions in assessing whether activities are “green” or “sustainable.” Without limiting any of the statements contained herein, we make no representation or warranty as to whether any of our securities constitutes a green or sustainable security or conforms to present or future investor expectations or objectives for green or sustainable investing. For information on characteristics of a security, use of proceeds, a description of applicable project(s) and/or any other relevant information, please reference the offering documents for such security.

    This document may contain inactive textual addresses to internet websites operated by us and third parties. Reference to such websites is made for information purposes only, and information found at such websites is not incorporated by reference into this document. ING does not make any representation or warranty with respect to the accuracy or completeness of, or take any responsibility for, any information found at any websites operated by third parties. ING specifically disclaims any liability with respect to any information found at websites operated by third parties. ING cannot guarantee that websites operated by third parties remain available following the publication of this document, or that any information found at such websites will not change following the filing of this document. Many of those factors are beyond ING’s control.

    Any forward-looking statements made by or on behalf of ING speak only as of the date they are made, and ING assumes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information or for any other reason.

    This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States or any other jurisdiction.


    Continue Reading

  • Cocoa and tea may protect your heart from the hidden damage of sitting

    Cocoa and tea may protect your heart from the hidden damage of sitting

    New findings from the University of Birmingham suggest that regularly eating foods rich in flavanols, including tea, berries, apples, and cocoa, may help protect men’s blood vessels from the negative effects that occur during long periods of…

    Continue Reading

  • Cocoa and tea may protect your heart from the hidden damage of sitting

    Cocoa and tea may protect your heart from the hidden damage of sitting

    New findings from the University of Birmingham suggest that regularly eating foods rich in flavanols, including tea, berries, apples, and cocoa, may help protect men’s blood vessels from the negative effects that occur during long periods of…

    Continue Reading

  • RHOA lactylation at oncogenic hotspots promotes oncogenic activity and protein stabilization | Molecular Cancer

    RHOA lactylation at oncogenic hotspots promotes oncogenic activity and protein stabilization | Molecular Cancer

    Supplementary Material 1: Supplementary Fig. 1. a-c, Kaplan-Meier survival analysis for OS (a), RFS (b) and DMFS (c) of patients in an aggregate breast cancer dataset according to RHOA expression status. The p value was determined using the…

    Continue Reading

  • Siddique SS, Suelves AM, Baheti U, Foster CS (2013 Jan-Feb) Glaucoma and uveitis. Surv Ophthalmol. 58(1):1–10. https://doi.org/10.1016/j.survophthal.2012.04.006

  • Neri P, Azuara-Blanco A, Forrester JV (2004) Incidence of glaucoma in patients with uveitis. J Glaucoma 13(6):461–465. https://doi.org/10.1097/01.ijg.0000146391.77618.d0

    Google Scholar 

  • Merayo-Lloves J, Power WJ, Rodriguez A, Pedroza-Seres M, Foster CS (1999) Secondary glaucoma in patients with uveitis. Ophthalmologica 213(5):300–304. https://doi.org/10.1159/000027443

    Google Scholar 

  • Takahashi T, Ohtani S, Miyata K, Miyata N, Shirato S, Mochizuki M (2002 Sep-Oct) A clinical evaluation of uveitis-associated secondary glaucoma. Jpn J Ophthalmol 46(5):556–562. https://doi.org/10.1016/s0021-5155(02)00549-x

  • Heinz C, Koch JM, Zurek-Imhoff B, Heiligenhaus A (2009) Prevalence of uveitic secondary glaucoma and success of nonsurgical treatment in adults and children in a tertiary referral center. Ocul Immunol Inflamm 17(4):243–248. https://doi.org/10.1080/09273940902913035

  • Dick AD, Tundia N, Sorg R, Zhao C, Chao J, Joshi A, Skup M (2016) Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. Ophthalmology. ;123(3):655 – 62. https://doi.org/10.1016/j.ophtha.2015.10.028. Epub 2015 Dec 19. Erratum in: Ophthalmology. 2016;123(11):2439. https://doi.org/10.1016/j.ophtha.2016.09.006.

  • Daniel E, Pistilli M, Kothari S, Khachatryan N, Kaçmaz RO, Gangaputra SS, Sen HN, Suhler EB, Thorne JE, Foster CS, Jabs DA, Nussenblatt RB, Rosenbaum JT, Levy-Clarke GA, Bhatt NP, Kempen JH, Systemic Immunosuppressive Therapy for Eye Diseases Research Group (2017) Risk of ocular hypertension in adults with noninfectious uveitis. Ophthalmology 124(8):1196–1208. https://doi.org/10.1016/j.ophtha.2017.03.041Epub 2017 Apr 19

    Google Scholar 

  • Niederer RL, Wong ABC, Ma T, Chew S, Sims J (2023) Predictors of glaucoma in patients with uveitis and scleritis. Eye (Lond) 37(6):1254–1257. https://doi.org/10.1038/s41433-022-02101-7Epub 2022 May 24

    Google Scholar 

  • Ma T, Sims JL, Bennett S, Chew S, Niederer RL (2022) High rate of conversion from ocular hypertension to glaucoma in subjects with uveitis. Br J Ophthalmol 106(11):1520–1523. https://doi.org/10.1136/bjophthalmol-2021-318809Epub 2021 May 21

    Google Scholar 

  • Liu X, Kelly SR, Montesano G, Bryan SR, Barry RJ, Keane PA, Denniston AK, Crabb DP (2019) Evaluating the impact of uveitis on visual field progression using Large-Scale Real-World data. Am J Ophthalmol 207:144–150 Epub 2019 Jun 26

    Google Scholar 

  • Carreño E, Villarón S, Portero A, Herreras JM, Maquet JA, Calonge M (2011) Surgical outcomes of uveitic glaucoma. J Ophthalmic Inflamm Infect 1(2):43–53. https://doi.org/10.1007/s12348-010-0012-8Epub 2010 Nov 18

    Google Scholar 

  • Halkiadakis I, Konstantopoulou K, Tzimis V, Papadopoulos N, Chatzistefanou K, Markomichelakis NN (2024) Update on diagnosis and treatment of uveitic glaucoma. J Clin Med 13(5):1185. https://doi.org/10.3390/jcm13051185

    Google Scholar 

  • Almobarak FA, Alharbi AH, Morales J, Aljadaan I (2018) The influence of mitomycin C concentration on the outcome of trabeculectomy in uveitic glaucoma. Int Ophthalmol 38(6):2371–2379. https://doi.org/10.1007/s10792-017-0737-6Epub 2017 Oct 14

    Google Scholar 

  • Iwao K, Inatani M, Seto T, Takihara Y, Ogata-Iwao M, Okinami S, Tanihara H (2014) Long-term outcomes and prognostic factors for trabeculectomy with mitomycin C in eyes with uveitic glaucoma: a retrospective cohort study. J Glaucoma 23(2):88–94. https://doi.org/10.1097/IJG.0b013e3182685167

    Google Scholar 

  • Hoffmann EM, Hengerer F, Klabe K, Schargus M, Thieme H, Voykov B (2021) Aktuelle Glaukomchirurgie [Glaucoma surgery today]. Ophthalmologe. ;118(3):239–247. German. https://doi.org/10.1007/s00347-020-01146-x. Erratum in: Ophthalmologe. 2021;118(Suppl 2):183. https://doi.org/10.1007/s00347-021-01457-7.

  • Almobarak FA, Alharbi AH, Aljadaan I, Aldhibi H (2021) Long-term outcomes of initial trabeculectomy in glaucoma associated with granulomatous and non-granulomatous uveitis. Int Ophthalmol 41(10):3459–3470. https://doi.org/10.1007/s10792-021-01910-1Epub 2021 Jun 7

    Google Scholar 

  • Bitossi A, Mattioli I, Bettiol A, Palermo A, Malandrino D, Bacherini D, Virgili G, Giansanti F, Vannozzi L, Silvestri E (2023) Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review. Expert Rev Clin Immunol 19(5):549–560 Epub 2023 Mar 27

    Google Scholar 

  • Sonoda KH, Hasegawa E, Namba K, Okada AA, Ohguro N, Goto H, JOIS (Japanese Ocular Inflammation Society) Uveitis Survey Working Group (2021) Epidemiology of uveitis in japan: a 2016 retrospective nationwide survey. Jpn J Ophthalmol 65(2):184–190. https://doi.org/10.1007/s10384-020-00809-1Epub 2021 Mar 11

    Google Scholar 

  • Chauhan K, Tyagi M (2024) Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond. Front Ophthalmol (Lausanne) 4:1412930. https://doi.org/10.3389/fopht.2024.1412930

    Google Scholar 

  • Kalogeropoulos D, Sung VC, Curr Glaucoma J Pract (2018) Sep-Dec ;12(3):125–138. https://doi.org/10.5005/jp-journals-10028-1257

  • Pillai MR, Balasubramaniam N, Wala N, Mathews AM, Tejeswi B, Krishna H, Ishrath D, Rathinam SR, Sithiq Uduman SM (2024) Glaucoma in uveitic eyes: long-term clinical course and management measures. Ocul Immunol Inflamm 32(6):1041–1047 Epub 2023 May 4

    Google Scholar 

  • Mosaed S (2020) Ab interno trabeculotomy in uveitic glaucoma: confirmation of original results with extended applications. Clin Exp Ophthalmol 48(1):12–13. https://doi.org/10.1111/ceo.13699

    Google Scholar 

  • Ikegawa W, Suzuki T, Namiguchi K, Mizoue S, Shiraishi A, Ohashi Y (2016) Changes in anterior segment morphology of Iris Bombe before and after laser peripheral iridotomy in patients with uveitic secondary glaucoma. J Ophthalmol 2016:8496201. https://doi.org/10.1155/2016/8496201

    Google Scholar 

  • Škrlová E, Svozílková P, Heissigerová J, Fichtl M (2023) Pathogenesis and current methods of treatment, of secondary uveitic glaucoma. a review. Cesk Slov Oftalmol 79(3):111–115 English. https://doi.org/10.31348/2023/7

  • Shrestha S, Thapa M, Shah DN (2014) Pattern of intraocular pressure fluctuation in uveitic eyes treated with corticosteroids. Ocul Immunol Inflamm 22(2):110–115. https://doi.org/10.3109/09273948.2013.824106

    Google Scholar 

  • Razeghinejad MR, Katz LJ (2012) Steroid-induced iatrogenic glaucoma. Ophthalmic Res 47(2):66–80. https://doi.org/10.1159/000328630

    Google Scholar 

  • Alaghband P, Baneke AJ, Galvis E, Madekurozwa M, Chu B, Stanford M, Overby D, Lim KS (2019) Aqueous humor dynamics in uveitic eyes. Am J Ophthalmol 208:347–355 Epub 2019 Aug 30

    Google Scholar 

  • Yorio T, Patel GC, Clark AF (2020) Glucocorticoid-induced ocular hypertension: origins and new approaches to minimize. Expert Rev Ophthalmol 15(3):145–157 Epub 2020 May 14

    Google Scholar 

  • Chang SM, St Peter DM, Im LT, Munir WM, Schocket LS (2022) Dexamethasone implant migration in an eye with congenital glaucoma: a case report and review of the literature. Eur J Ophthalmol 32(5):NP46–NP50. Epub 2021 Mar 29 https://doi.org/10.1177/11206721211005696

    Google Scholar 

  • Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. ;388(10050):1183-92. https://doi.org/10.1016/S0140-6736(16)31339-3. Epub 2016 Aug 16. Erratum in: Lancet. 2016;388(10050):1160. doi: 10.1016/S0140-6736(16)31538-0

  • Suhler EB, Adán A, Brézin AP, Fortin E, Goto H, Jaffe GJ, Kaburaki T, Kramer M, Lim LL, Muccioli C, Nguyen QD, Van Calster J, Cimino L, Kron M, Song AP, Liu J, Pathai S, Camez A, Schlaen A, van Velthoven MEJ, Vitale AT, Zierhut M, Tari S, Dick AD (2018) Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing Open-Label study: VISUAL III. Ophthalmology 125(7):1075–1087. https://doi.org/10.1016/j.ophtha.2017.12.039Epub 2018 Feb 9

    Google Scholar 

  • Inoue T (2017) [The science of glaucoma surgery -Filtration surgery and the role of Cytokines]. Nippon Ganka Gakkai Zasshi 121(3):314–334 Japanese

    Google Scholar 

  • Lee J, Choi JA, Ju HH, Kim JE, Paik SY, Rao PV (2021) Role of MCP-1 and IL-8 in viral anterior uveitis, and contractility and fibrogenic activity of trabecular meshwork cells. Sci Rep 11(1):14950. https://doi.org/10.1038/s41598-021-94391-2

    Google Scholar 

  • Suzuki K, Iwata D, Namba K, Hase K, Hiraoka M, Murata M, Kitaichi N, Foxton R, Ishida S (2023) Involvement of angiopoietin 2 and vascular endothelial growth factor in uveitis. PLoS ONE 18(11):e0294745. https://doi.org/10.1371/journal.pone.0294745

    Google Scholar 

  • Singh S, Anshita D, Ravichandiran V (2021) MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol. 101(Pt B):107598. https://doi.org/10.1016/j.intimp.2021.107598

Continue Reading

  • Sez6L2 autoimmunity induces cerebellar ataxia in mice | Journal of Neuroinflammation

    Sez6L2 autoimmunity induces cerebellar ataxia in mice | Journal of Neuroinflammation

  • Garza M, Piquet AL. Update in autoimmune movement disorders: newly described antigen targets in autoimmune and paraneoplastic cerebellar ataxia. Front Neurol. 2021;12:683048.

    Google Scholar 

  • Yaguchi H, Yabe I,…

  • Continue Reading